Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tozorakimab - AstraZeneca

Next Previous
Drug Profile

Tozorakimab - AstraZeneca

Alternative Names: Anti-(human interleukin 33) (human monoclonal MEDI3506 gamma1-chain); Dimer; Disulfide with human monoclonal MEDI3506 lambda-chain; Immunoglobulin G1; MEDI-3506

Latest Information Update: 15 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Developer AstraZeneca
  • Class Anti-inflammatories; Antiasthmatics; Antivirals; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin-33 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease; Respiratory insufficiency
  • Phase II Asthma; COVID 2019 infections
  • Phase I Unspecified
  • Discontinued Atopic dermatitis; Diabetic nephropathies

Most Recent Events

  • 12 Mar 2024 AstraZeneca plans phase I pharmacokinetics trial in healthy volunteers (In adults) in Germany in April 2024 (SC) (NCT06304961)
  • 31 Dec 2023 Discontinued - Phase-II for Diabetic nephropathies (In the elderly, In adults) in USA, Japan, Argentina, Canada, Chile, Peru, South Korea (unspecified route) (AstraZeneca pipeline, February 2024) (NCT04170543)
  • 13 Nov 2023 AstraZeneca completes the phase II FRONTIER-4 in Chronic obstructive pulmonary disease (In adults, In the elderly) in the US, Canada, Czechia, Denmark, Germany, Hungary, Israel, Netherlands, New Zealand, Poland, South Africa, Spain, Taiwan UK (NCT04631016) (EudraCT-2020-000571-20)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top